Lunit
Lunit makes AI that reads mammograms and scans to flag cancer for radiologists.
The call
Lunit grows fast overseas but still loses money, leaned on a dilutive raise, and faces both a key customer and bigger AI models building rival tools.
Lunit makes artificial intelligence software that reads medical images like mammograms and pathology slides to help doctors spot disease. The company has real government approvals and a large database of 100 million mammograms, plus growing sales up 53 percent, but that lead is shrinking fast. RadNet, one of Lunit's biggest customers, is now using its own AI tool called DeepHealth instead, GE Healthcare is backing DeepHealth too, and well-funded competitors like Aidoc and Paige are building broader AI systems that work on many types of scans at once, which could make Lunit's narrow tools less valuable. The one thing that could save the company is its SCOPE division, which finds disease markers for drug companies, growing 90 percent a year; if SCOPE becomes a stable, repeating business before the imaging side gets squeezed out, Lunit could survive, but another major cash drain or investor dilution would signal real trouble ahead.
Why
01
AI pressure: Aidoc (CARE1 multi-indication model) and Paige (pathology foundation model with Microsoft). Aidoc and Paige build multi-indication AI models that could replace Lunit's single-cancer-type products over time. Could AI do the core job? Only partly.
02
Bigger players: RadNet's DeepHealth, backed by a deepening GE Healthcare partnership. RadNet already runs its own DeepHealth breast AI while GE, Lunit's own distribution partner, expands ties with that same rival. Could a giant copy it? Yes, easily.
03
What protects it. US and Korean regulatory clearances, a huge mammogram dataset from Volpara, and hospital contracts that are slow to switch.
What would change this call
RadNet renews or expands its Lunit contract versus shifting further to DeepHealth. Shows whether Lunit is losing its largest customer to an in-house rival.
GE Healthcare announces bundling or defaulting to DeepHealth on new hardware. Would show Lunit's key distribution partner favoring a competing product.
Lunit needs another dilutive capital raise after the 2026 rights offering. Would show balance-sheet strain deepening despite revenue growth.
GE Healthcare announces bundling or defaulting to DeepHealth on new hardware. Would show Lunit's key distribution partner favoring a competing product.
Lunit needs another dilutive capital raise after the 2026 rights offering. Would show balance-sheet strain deepening despite revenue growth.
Key numbers
- FY2025 revenue ₩83.1B, up 53% YoY
- Q1 2026 revenue ₩23.95B, up 25% YoY
- ₩250B rights offering covers ₩197B CB liability
Named risks
- Dilutive KRW250B rights offering to cover Volpara-related CB liability signals balance-sheet fragility.
- OEM partner GE Healthcare deepening ties with rival DeepHealth threatens distribution channel.
- Foundation-model rivals Aidoc and Paige could commoditize narrow-indication imaging models.
- Persistent operating losses despite revenue growth, e.g. KRW41.9B loss in H1 2025.
- Shareholder governance concerns over dilution and CB overhang raised at Mar 2026 meeting.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| RadNet / DeepHealth | gaining on | DeepHealth got 2 FDA clearances Jun 2026 and expanded GE tie-up Apr 2026 while serving as Lunit customer |
| GE Healthcare | contesting | Deepened DeepHealth mammography partnership Apr 16 2026 while also distributing Lunit imaging AI |
| Aidoc | gaining on | CARE1 got FDA Breakthrough Sept 2025, raised Goldman-led Series E Apr 2026 |
| Paige | contesting | Building million-slide pathology foundation model with Microsoft, threatens SCOPE niche |
| VUNO | contesting | South Korean peer VUNO grew revenue 35% in 2025 with narrowing losses |
Questions people ask
- Is Lunit profitable in 2026?
- Not yet. Q1 2026 revenue rose 25% YoY to KRW23.95 billion and operating loss narrowed 35%, but Lunit still posted a loss. The company targets EBITDA breakeven by end of 2026, per its May 12, 2026 earnings report.
- Who owns Lunit?
- Lunit is publicly traded on South Korea's KOSDAQ under ticker 328130, listed July 21, 2022 at KRW30,000 per share with a ~30% first-day surge. It has no single controlling parent; ownership is spread across institutional and retail shareholders after a 2026 rights offering.
- Could AI replace Lunit's business?
- Lunit itself sells AI cancer-detection software, but its narrow-indication models face threats from foundation-model rivals: Aidoc's CARE1 got FDA Breakthrough Device status in September 2025, and Paige is building a million-slide pathology foundation model with Microsoft.
- Is RadNet Lunit's biggest competitor?
- RadNet's subsidiary DeepHealth builds a competing in-house breast AI (Breast Suite), received two new FDA clearances in June 2026, and GE Healthcare expanded its DeepHealth partnership in April 2026, even as RadNet also uses Lunit/Volpara products.
- What is Lunit SCOPE and how is it growing?
- Lunit SCOPE is a pathology and biomarker AI product used for oncology drug companion diagnostics. Its Q1 2026 revenue grew 90% year-over-year to KRW1.68 billion, and Lunit signed a December 2025 collaboration with Daiichi Sankyo to integrate SCOPE into drug development.
- Does Lunit partner with Microsoft?
- Yes. Lunit's CTO disclosed on April 7, 2026 a jointly developed medical AI platform with Microsoft dating to 2024/2025, and Lunit is a launch partner for Microsoft's Dragon Copilot radiology reporting tool, with commercialization targeted within 2026.
Timeline
- 2026-06-25DeepHealth (RadNet) gets two FDA clearances adding cardiovascular and prior-exam features to Breast Suite
- 2026-05-12Lunit posts record Q1 revenue KRW23.95B, up 25% YoY, operating loss narrows 35%
- 2026-04-24Lunit finalizes rights offering with subscriptions around KRW211.5 billion
- 2026-04-16GE Healthcare expands mammography partnership with RadNet's DeepHealth subsidiary
- 2026-04-07Lunit CTO reveals joint Microsoft medical AI platform and Dragon Copilot launch partnership
- 2026-03-01Shareholders press Lunit management on dilution and CB overhang at meeting
- 2026-02-02Lunit announces KRW250B rights offering to neutralize KRW197B CB liability
- 2025-12-01Lunit signs collaboration with Daiichi Sankyo to integrate SCOPE into oncology drug development
- 2024-05-28Lunit completes $193M acquisition of Volpara Health Technologies
- 2022-07-21Lunit debuts on KOSDAQ at KRW30,000/share, surging ~30% on first day
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- After years of losses, Korea's medical AI sector edges toward profitability (2026-02-20)
- Lunit achieves record first half revenue but faces wider operating loss (2025-08-13)
- Lunit lifts Q1 revenue 25% as overseas sales surge and losses narrow (2026-05-12)
- Lunit posts record Q1 sales as overseas revenue drives growth (2026-05-13)
- Radiology AI vendor Lunit completes acquisition of rival Volpara for $193M (2024-05-28)
- Lunit shifts to profitability-first strategy with ₩250 bil. rights offering (2026-02-02)
- Lunit tops rights offering subscriptions, shores up finances for growth (2026-04-24)
- Lunit shareholders press management on dilution, CB overhang and governance concerns (2026-04-01)
- AI-based Cancer Solution Pioneer Lunit Makes Market Debut (2022-07-21)
- Lunit Cancer Screening - Headcount, Funding & Open Jobs (2026-06-25)
- Lunit Posts Record Q1 Revenue of 24 Billion Won on Overseas Growth (2026-05-12)
- Lunit secures 5-year contract with SEHA in UAE for AI-based breast cancer screening programme